Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

[1]  I. Dick,et al.  Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.

[2]  M. Maio,et al.  Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme , 2013, Cancer Immunology, Immunotherapy.

[3]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Berking,et al.  The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network , 2013, PloS one.

[5]  J. Wolchok,et al.  Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 , 2012 .

[6]  J. Wolchok,et al.  Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials , 2012 .

[7]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Hoogsteden,et al.  New Roads Open Up for Implementing Immunotherapy in Mesothelioma , 2012, Clinical & developmental immunology.

[9]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Ceresoli,et al.  Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.

[11]  J. Kirkwood,et al.  Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Chasalow,et al.  Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.

[13]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[14]  M. Maio,et al.  Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. , 2010, Seminars in oncology.

[15]  J. Wolchok,et al.  Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. , 2010, Seminars in oncology.

[16]  A. Korman,et al.  Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. , 2010, Seminars in oncology.

[17]  A. Ribas.  Clinical development of the anti-CTLA-4 antibody tremelimumab. , 2010, Seminars in oncology.

[18]  M. Maio,et al.  The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. , 2010, Seminars in oncology.

[19]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[20]  P. LoRusso,et al.  Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells , 2010, Clinical Cancer Research.

[21]  J. Wolchok,et al.  Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.

[22]  G. Ceresoli,et al.  Second-line treatment for malignant pleural mesothelioma. , 2010, Cancer treatment reviews.

[23]  M. Grégoire.  What's the place of immunotherapy in malignant mesothelioma treatments? , 2010, Cell adhesion & migration.

[24]  Axel Hoos,et al.  Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.

[25]  R. Ramlau,et al.  Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Gridelli,et al.  Multidisciplinary treatment of malignant pleural mesothelioma. , 2007, The oncologist.

[27]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[28]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Tsao.  Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study , 2012 .

[31]  A. Cattelan,et al.  Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). , 1999, Journal of immunotherapy.

[32]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.